TABLE II -.
Analysis of the evolution of the LP of the different generic Lenalidomide medicines approved in Spain with respect to the innovative drug
| Drug type and company | CIPM date | Marketing authorisation date | CIPM LP (€/mg)* | Interval since 1st Gx LP approval by CIPM (years) | Price difference vs innovative price | Price difference vs 1st Gx LP |
|---|---|---|---|---|---|---|
| Innovative (BMS) | 25/05/2007 | 14/06/2007 | 11.518 | NA | NA | NA |
| Generic 1 (Cipla) | 14/10/2020 | 10/03/2020 | 4.678 | 0 | −59% | NA |
| Generic 2 (Accord) | 28/02/2021 | 27/11/2020 | 4.678 | 0.4 | −59% | 0% |
| Generic 3 (Reddy Pharma) | 01/12/2020 | 01/12/2020 | 4.678 | 0.1 | −59% | 0% |
| Generic 4 (Stada) | 27/11/2020 | 20/03/2021 | 4.678 | 0.1 | −59% | 0% |
| Generic 5 (Kern) | 31/03/2021 | 01/10/2020 | 4.678 | 0.5 | −59% | 0% |
| Generic 6 (Krka) | 31/05/2021 | 20/03/2021 | 4.678 | 0.6 | −59% | 0% |
| Generic 7 (Viso) | 30/06/2021 | 09/02/2021 | 4.678 | 0.7 | −59% | 0% |
| Generic 8 (Teva) | 31/07/2021 | 01/08/2019 | 4.678 | 0.8 | −59% | 0% |
| Generic 9 (Fresenius) | 31/10/2021 | 09/02/2021 | 3.977 | 1.0 | −65% | −15% |
| Generic 10 (Mylan) | 31/10/2021 | 25/06/2021 | 3.977 | 1.0 | −65% | −15% |
| Generic 11 (Sandoz) | 31/10/2021 | 09/02/2021 | 3.977 | 1.0 | −65% | −15% |
| Generic 12 (Aurovitas) | 30/11/2021 | 01/10/2021 | 3.977 | 1.1 | −65% | −15% |
| Generic 13 (Sun) | 31/12/2021 | 01/10/2021 | 3.977 | 1.2 | −65% | −15% |
| Generic 14 (Tarbis) | 31/12/2021 | 01/09/2020 | 3.977 | 1.2 | −65% | −15% |
* In the case of the innovative drug, the LP indicated is the one prior to the marketing of the f irst generic, not the initial LP.
CIPM = Comisión Interministerial de Precios de los Medicamentos; Gx = generic medicines; LP = list price.